Ropinirole for restless legs syndrome: A placebo-controlled crossover trial

C. H. Adler, R. A. Hauser, K. Sethi, J. N. Caviness, L. Marlor, W. M. Anderson, J. G. Hentz

Research output: Contribution to journalArticlepeer-review

81 Scopus citations


The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

Original languageEnglish (US)
Pages (from-to)1405-1407
Number of pages3
Issue number8
StatePublished - Apr 27 2004

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Ropinirole for restless legs syndrome: A placebo-controlled crossover trial'. Together they form a unique fingerprint.

Cite this